Incyte Corp
NASDAQ:INCY
Incyte Corp
Cash from Operating Activities
Incyte Corp
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Incyte Corp
NASDAQ:INCY
|
Cash from Operating Activities
$496.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
49%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Incyte Corp's Cash from Operating Activities?
Cash from Operating Activities
496.5m
USD
Based on the financial report for Dec 31, 2023, Incyte Corp's Cash from Operating Activities amounts to 496.5m USD.
What is Incyte Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
49%
Over the last year, the Cash from Operating Activities growth was -49%.